|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.520 USD | -4.86% |
|
-9.69% | +26.37% |
| Apr. 10 | Replimune's drug for advanced skin cancer fails to win FDA nod again | RE |
| Mar. 20 | Iovance Biotherapeutics, Inc. Announces Retirement of Wendy Yarno as Member of the Board of Directors | CI |
| Capitalization | 1.52B 1.3B 1.19B 1.13B 2.08B 143B 2.13B 14.01B 5.52B 68.48B 5.72B 5.6B 243B | P/E ratio 2026 * |
-7.42x | P/E ratio 2027 * | -15.4x |
|---|---|---|---|---|---|
| Enterprise value | 1.35B 1.15B 1.05B 997M 1.84B 126B 1.88B 12.38B 4.88B 60.53B 5.05B 4.95B 215B | EV / Sales 2026 * |
3.62x | EV / Sales 2027 * | 2.7x |
| Free-Float |
90.74% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Iovance Biotherapeutics, Inc.
| 1 day | -5.00% | ||
| 1 week | -9.69% | ||
| Current month | -1.71% | ||
| 1 month | -4.96% | ||
| 3 months | +28.25% | ||
| 6 months | +60.47% | ||
| Current year | +26.37% |
| 1 week | 3.4 |  | 3.97 |
| 1 month | 3.18 | | 4.31 |
| Current year | 2.21 | | 5.63 |
| 1 year | 1.64 | | 5.63 |
| 3 years | 1.64 | | 18.33 |
| 5 years | 1.64 | | 33.55 |
| 10 years | 1.64 | | 54.21 |
| Manager | Title | Age | Since |
|---|---|---|---|
Frederick Vogt
CEO | Chief Executive Officer | 52 | 2021-06-17 |
Corleen Roche
DFI | Director of Finance/CFO | 60 | 2025-08-05 |
Brian Shew
CTO | Chief Tech/Sci/R&D Officer | - | 2021-06-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Ryan Maynard
BRD | Director/Board Member | 56 | 2015-02-15 |
| Director/Board Member | 58 | 2016-06-06 | |
Iain Dukes
CHM | Chairman | 67 | 2016-08-15 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -4.86% | -9.69% | +7.48% | -39.47% | 1.52B | |
| +0.49% | -1.50% | +7.71% | +44.46% | 2.66B | |
| +0.10% | -1.51% | -17.92% | -41.79% | 2.24B | |
| -0.42% | -2.89% | +101.28% | +71.03% | 2.19B | |
| +1.04% | +19.66% | +18.28% | +149.11% | 1.06B | |
| +4.10% | +0.99% | +272.30% | - | 1.02B | |
| -0.20% | +3.33% | -1.97% | +1.02% | 777M | |
| -0.35% | -5.77% | -14.29% | -14.56% | 659M | |
| +1.22% | +5.57% | +91.45% | -74.29% | 539M | |
| +1.88% | -2.14% | - | - | 432M | |
| Average | +0.28% | +1.28% | +51.59% | +11.94% | 1.31B | |
| Weighted average by Cap. | -0.06% | +0.53% | +43.28% | +19.72% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 372M 318M 291M 276M 508M 34.91B 520M 3.42B 1.35B 16.72B 1.4B 1.37B 59.32B | 528M 451M 413M 391M 722M 49.55B 738M 4.86B 1.91B 23.73B 1.98B 1.94B 84.21B |
| Net income | -201M -172M -158M -149M -275M -18.89B -281M -1.85B -729M -9.05B -755M -740M -32.1B | -94.98M -81.05M -74.34M -70.31M -130M -8.91B -133M -873M -344M -4.27B -356M -349M -15.14B |
| Net Debt | -177M -151M -138M -131M -242M -16.58B -247M -1.63B -640M -7.94B -663M -650M -28.18B | -97.95M -83.58M -76.66M -72.51M -134M -9.19B -137M -900M -355M -4.4B -367M -360M -15.61B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-04-22 | 3.445 $ | -6.89% | 14,187,465 |
| 26-04-21 | 3.700 $ | -2.12% | 10,956,783 |
| 26-04-20 | 3.780 $ | -2.07% | 9,751,117 |
| 26-04-17 | 3.860 $ | +1.58% | 10,684,185 |
| 26-04-16 | 3.800 $ | -0.52% | 11,014,677 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- IOVA Stock
Select your edition
All financial news and data tailored to specific country editions
